Highlights
Galenica continues to grow in the 2024 financial year: the Galenica Group achieved strong growth with sales up 4.7% in the 2024 financial year and generated consolidated net sales of CHF 3,921.1 million and gained market share.
Highlights of the 2024 financial year
Consultations and healthcare services
193,000
+39% year on year
Generic substitution rate in pharmacies
79.2%
+4% year on year
Employee survey – Opinio
76
Satisfaction and motivation rate among Galenica Group employees
Adjusted1) EBIT increased by 10.3% to CHF 211.0 million. Excluding the one-off special factors in the previous year, adjusted1) earnings before interest and taxes (EBIT) would have grown by 4.9%. Adjusted1) net profit from continuing operations increased by a strong 13.4% to CHF 183.2 million. Thanks to this good result, the Board of Directors will propose to the annual general meeting a dividend of CHF 2.30 per share, representing an increase of 4.5%.
Highlights from the 2024 financial year
- The pharmacy network (excluding Coop Vitality) continued to develop dynamically: twelve pharmacies were acquired, two new pharmacies were opened and four were closed or merged with other locations.
- Thanks to high demand for prescription-only medications, Galenica pharmacies grew organically by 2.7% and gained further market share.
- Around 193,000 customers made use of the healthcare services and consultations offered by Galenica pharmacies in 2024, 39% more than in the previous year. Demand for vaccinations increased by 20%.
- Verfora’s export business performed very positively with organic growth of 15.1%. This pleasing result was driven by higher demand for Perskindol® in Asia and by sooner-than-expected product deliveries abroad in anticipation of a regulatory change.
- Growth drivers in the “Services for Professionals” sector (+7.5%) were once again Lifestage Solutions and Medifilm in business with care homes and home care organisations. In 2024, Medifilm put two new blister packaging machines into operation and increased the number of patients by around 10%.
- In the “Wholesale” sector, very strong growth of 7.8% was achieved in the doctor’s segment, resulting in market share gains.
- Health Supply Ltd., a joint venture with Planzer, developed according to plan in 2024. Galexis was able to reduce complexity by bundling outsourced services.
- HCI Solutions has also developed positively. By the end of December, around 369 million CDS checks had been carried out (+33%), making an important contribution to patient safety.
1) Excluding the effects of IAS 19 and IFRS 16. See chapter “Alternative performance measures”.